Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

NCT03114527 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT03114527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03114527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 8, 2017
Completion date
December 31, 2026
Enrollment
48 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma